Health Care & Life Sciences » Biotechnology | Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
39,407.00
53,504.00
117,732.00
198,471.00
314,670.00
346,028
Depreciation, Depletion & Amortization
1,440.00
1,367.00
3,342.00
5,708.00
6,432.00
7,172
Other Funds
-
-
-
-
638.00
69,540
Funds from Operations
30,811.00
40,093.00
81,855.00
149,904.00
260,400.00
269,316
Changes in Working Capital
25,589.00
19,260.00
4,906.00
188,466.00
24,832.00
35,105
Net Operating Cash Flow
56,400.00
59,353.00
76,949.00
38,562.00
285,232.00
304,421
Capital Expenditures
1,294.00
2,216.00
20,164.00
9,915.00
4,627.00
Purchase/Sale of Investments
85,923.00
331,691.00
148,473.00
109,435.00
53,281.00
Net Investing Cash Flow
87,217.00
333,336.00
128,309.00
119,350.00
57,908.00
Net Financing Cash Flow
123,880.00
335,160.00
6,373.00
169,778.00
285,110.00
Net Change in Cash
19,737.00
57,529.00
57,733.00
88,990.00
58,030.00
Free Cash Flow
57,694.00
61,569.00
97,113.00
28,647.00
289,859.00
Deferred Taxes & Investment Tax Credit
3,842.00
-
-
-
-
-
Other Sources
-
571.00
-
-
-
Change in Capital Stock
123,880.00
335,160.00
6,373.00
169,778.00
284,472.00

About Agios Pharmaceuticals

View Profile
Address
88 Sidney Street
Cambridge Massachusetts 02139
United States
Employees -
Website http://www.agios.com
Updated 07/08/2019
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. Its product candidates include IDHIFA, ivosidenib, AG-881, AG-348, and AG-270.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.